Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present BioRestorative Therapies, Inc. (OTC: BRTX).

Full DD Report for BRTX

You must become a subscriber to view this report.


Recent News from (OTC: BRTX)

BioRestorative Therapies Appoints Wayne J. Olan, M.D. as Clinical Director of Regenerative Disc/Spine Program
MELVILLE, N.Y., May 07, 2018 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative" or the “Company") (OTC:BRTX), a life sciences company focused on stem cell-based therapies, today announced that Wayne J. Olan, M.D. has been appointed as Clinical Director of the Compan...
Source: GlobeNewswire
Date: May, 07 2018 09:45
BioRestorative Therapies Announces the Appointment of Adam D. Bergstein as Sr. VP, Planning and Business Development
MELVILLE, N.Y., Jan. 22, 2018 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative" or the “Company") (OTC:BRTX), a life sciences company focused on stem cell-based therapies, today announced the appointment of Adam Bergstein as Senior Vice President, Planning and Busi...
Source: GlobeNewswire
Date: January, 22 2018 10:59
BioRestorative Therapies Receives Notice of Allowance for Key Metabolic Patent in Japan
MELVILLE, N.Y., Oct. 17, 2017 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative" or the “Company") (OTC:BRTX), a life sciences company focused on stem cell-based therapies, today announced that the Japan Patent Office has issued BioRestorative a Notice of Allowance ...
Source: GlobeNewswire
Date: October, 17 2017 09:45
BioRestorative Therapies Announces Published Study of Licensed Technology to Treat Lumbar Degenerative Disc Disease
MELVILLE, N.Y., Oct. 05, 2017 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative" or the “Company") (OTC:BRTX), a life sciences company focused on stem cell-based therapies, today announced that an independent lower back pain study has been published in the Journal ...
Source: GlobeNewswire
Date: October, 05 2017 09:45
BioRestorative Therapies (BRTX) Investor Presentation - Slideshow
The following slide deck was published by BioRestorative Therapies, Inc. in conjunction with this Read more ...
Source: SeekingAlpha
Date: June, 15 2017 09:47
BioRestorative Therapies to Present at 6th Annual Marcum MicroCap Conference
MELVILLE, N.Y., June 14, 2017 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative" or the “Company") (OTCBB:BRTX), a life sciences company focused on stem cell-based therapies, today announced that Mark Weinreb, the Company’s CEO, will present a Company overvie...
Source: GlobeNewswire
Date: June, 14 2017 09:45
BioRestorative Therapies Receives Notice of Acceptance for Key Metabolic Patent in Australia
MELVILLE, N.Y., April 20, 2017 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative" or the “Company") (OTCBB:BRTX), a life sciences company focused on stem cell-based therapies, today announced the Australia Patent Office (APO), a division of IP Australia - an agency ...
Source: GlobeNewswire
Date: April, 20 2017 09:45
FDA OKs BioRestorative's mid-stage study of BRTX-100 as a treatment for degenerative disc disease
The FDA green lights BioRestorative Therapies ( OTCQB:BRTX ) to start a Phase 2 clinical trial assessing lead product candidate BRTX-100 for the treatment of lower back pain caused by protruding/bulging discs due to degenerative disc disease. More news on: BioRestorative Therapies, Inc.,...
Source: SeekingAlpha
Date: February, 08 2017 10:20
BioRestorative Therapies Receives FDA Clearance to Initiate Phase 2 Clinical Trial for the Treatment of Patients with Degenerative Disc Disease
MELVILLE, N.Y., Feb. 08, 2017 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BRT" or the “Company") (OTCBB:BRTX), a life sciences company focused on stem cell-based therapies, today announced that it has received clearance by the U.S. Food and Drug Administration (FDA) to comme...
Source: GlobeNewswire
Date: February, 08 2017 09:45
BioRestorative Therapies Receives FDA Clearance to Initiate Phase 2 Clinical Trial for the Treatment of Patients with Degenerative Disc Disease
BioRestorative Therapies Receives FDA Clearance to Initiate Phase 2 Clinical Trial for the Treatment of Patients with Degenerative Disc Disease
Source: OTC Markets
Date: February, 08 2017 00:00

 


About BioRestorative Therapies, Inc. (OTC: BRTX)

Logo for BioRestorative Therapies, Inc. (OTC: BRTX)

We develop therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Our two core programs are: Disc/Spine Program brtxDISCTM : Our lead cell therapy candidate, BRTX , is a product formulated from autologous cultured mesenchymal stem cells collected from bone marrow. We intend that the product will be used for the non surgical treatment of protruding and bulging lumbar discs in patients suffering from chronic lumbar disc disease. The treatment is intended for patients whose pain has not been alleviated by non invasive procedures and who potentially face the prospect of surgery. We have received clearance from the Food and Drug Administration to commence a Phase clinical trial using BRTX to treat chronic lower back pain due to degenerative disc disease related to protruding/bulging discs. Metabolic Program ThermoStem : We are developing a cell based therapy to target obesity and metabolic disorders using brown adipose fat derived stem cells to generate brown adipose tissue BAT . BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in the body may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes.

 

Contact Information

 

 

Current Management

  • Mark Weinreb / CEO
    • Mark Weinreb is an early pioneer in the field of regenerative medicine and cellular therapy and has significant experience in running public companies. He has served as our CEO since October , as our President since February , and as our Chairman since April . From February to January he served as the CEO and Chairman of Phase III Medical, Inc. where he orchestrated the acquisition of NS California, an adult stem cell collection company that became NeoStem, Inc. NASDAQ: NBS , a public international biopharmaceutical company. From June through October , Mr. Weinreb served as President and a director of NeoStem. In , Mr. Weinreb joined Bio Health Laboratories, Inc., a stateoftheart medical diagnostic laboratory. He became the laboratory administrator in and then an owner and the laboratory s Chief Operating Officer in . In such capacity, he oversaw all technical and business facets, including finance and laboratory science technology. In , Mr. Weinreb founded Big City Bagels, Inc., a national chain of franchised upscale bagel bakeries and became its Chairman and Chief Executive Officer. Big City Bagels went public in , and in Mr. Weinreb redirected the company and completed a merger with an Internet service provider. Mr. Weinreb received a Bachelor of Arts degree in from Northwestern University and a Master of Science degree in in Medical Biology from C.W. Post, Long Island University.
  • Mandy Clyde / VP, Ops., Corporate Secretary
    • Mandy Clyde has been our Vice President of Operations since August . She has served as our Corporate Secretary since December and served on our Board from September to April . From to , Mrs. Clyde served as Educational Envoy and then CME/CE Coordinator for Professional Resources in Management Education, an accredited provider of continuing medical education. She conducted needs assessments nationally to determine in which areas clinicians most needed current education. She also oversaw onsite educational meetings and analyzed data for outcomes reporting. From to , Mrs. Clyde served as surgical coordinator for Eye Surgery Associates and the Rand Eye Institute, two prominent physician practices in Florida. Mrs. Clyde has experience in medical editing for educational programs and is a published author of advanced scientific and clinical content on topics including Alzheimer s disease, breast cancer, sleep apnea and adult learning. She received a degree in Biology from Mercyhurst University.
  • Francisco Silva / VP, R amp D, Chief Scientist
    • Francisco Silva joined BRT in April . Mr. Silva is responsible for all laboratory operations and is involved in the development and growth of our stem cell programs. From to , Mr. Silva served as Chief Executive Officer of DV Biologics LLC, and as President of DaVinci Biosciences LLC, companies engaged in the commercialization of humanbased biologics for both research and therapeutic applications. From to , Mr. Silva was Vice President of Research and Development for PrimeGen Biotech LLC, a company engaged in the development of cellbased platforms. From to , he was a Research Scientist with PrimeGen Biotech and was responsible for the development of experimental designs that focused on germ line reprogramming stem cell platforms. Mr. Silva has taught courses in biology, anatomy and advanced tissue culture at California State Polytechnic University. He has obtained a number of patents relating to stem cells and has had numerous articles published with regard to stem cell research. Mr. Silva graduated from California State Polytechnic University with a degree in Biology. He also obtained a Graduate Presidential Fellowship and MBRS Fellowship from California State Polytechnic University.
  • Mark Weinreb / Chairman
    • Mark Weinreb is an early pioneer in the field of regenerative medicine and cellular therapy and has significant experience in running public companies. He has served as our CEO since October , as our President since February , and as our Chairman since April . From February to January he served as the CEO and Chairman of Phase III Medical, Inc. where he orchestrated the acquisition of NS California, an adult stem cell collection company that became NeoStem, Inc. NASDAQ: NBS , a public international biopharmaceutical company. From June through October , Mr. Weinreb served as President and a director of NeoStem. In , Mr. Weinreb joined Bio Health Laboratories, Inc., a stateoftheart medical diagnostic laboratory. He became the laboratory administrator in and then an owner and the laboratory s Chief Operating Officer in . In such capacity, he oversaw all technical and business facets, including finance and laboratory science technology. In , Mr. Weinreb founded Big City Bagels, Inc., a national chain of franchised upscale bagel bakeries and became its Chairman and Chief Executive Officer. Big City Bagels went public in , and in Mr. Weinreb redirected the company and completed a merger with an Internet service provider. Mr. Weinreb received a Bachelor of Arts degree in from Northwestern University and a Master of Science degree in in Medical Biology from C.W. Post, Long Island University.

Current Share Structure

  • Market Cap: $20,683,166 - 03/09/2018
  • Authorized: 30,000,000 - 02/08/2018
  • Issue and Outstanding: 6,137,438 - 02/08/2018
  • Float: 922,730 - 04/06/2017

 


Recent Filings from (OTC: BRTX)

Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: April, 02 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 02 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: January, 22 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: December, 22 2017
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: November, 20 2017
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: November, 14 2017
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: November, 02 2017
Free Writing Prospectus
Filing Type: FWPFiling Source: edgar
Filing Date: October, 06 2017
General form for registration of securities under the Securities Act of 1933
Filing Type: S-1Filing Source: edgar
Filing Date: October, 05 2017
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: September, 14 2017

 

 


Daily Technical Chart for (OTC: BRTX)

Daily Technical Chart for (OTC: BRTX)


Stay tuned for daily updates and more on (OTC: BRTX)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: BRTX)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

The Subway Trader
@TheSubwayTrader

 

 


Disclaimer: The Subway Trader publishes reports providing information on selected companies. The Subway Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. The Subway Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in BRTX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. The Subway Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. The Subway Trader does not own any shares of BRTX and does not buy, sell, or trade any shares of BRTX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by The Subway Trader. All rights reserved. Our Full Disclaimer: http://thesubwaytrader.com/disclaimer/